Skip to main content

Advertisement

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling

Fig. 5

Metagene classifier of time-to-progression under BE. The left panel displays the classification of low- versus high-risk patients based on the 91-gene metagene. The central panel shows the classification obtained by the KMplotter online validation tool using a multigene classifier. The right panel shows the classification obtained by the external CIT validation dataset. Hazard ratios and log rank test p values are reported in the upper right corner of the each panel

Back to article page